David Khayat – författare

David Khayat led France’s war against cancer and has been in the medical trenches for thirty years. In this international bestseller, he shares his knowledge on the role of diet and lifestyle in getting different types of cancer and how to bolster the body against those risks. Bringing together his own cross-national studies with those of other top cancer experts, Khayat empowers readers with the latest nutritional knowledge. He guides them through all food groups, including supplements and beverages, often supplying surprising advice. Men and women of all ages will find tips to meet their specific needs in this accessible, user-friendly guide. Handy charts at the end of the book distill information on the best—and worst—foods, habits and cooking methods for every body.

The subject of this book is the study of the relative roles of CT and MRI for all tumors; by contrast comparison with clinical results, the respective indications for these techniques are clarified, in term of diagnosis treatment planning and survey with educational presentation of radiologic signs.

This volume describes selected examples of both diagnostic and therapeutic progress in areas of Hematological malignancies and common human solid tumors, with emphasis in research that has immediate or very short-term clinical application. The expanded understanding of the processes of malignant transfomation, invasion and metastasis has contributed to exciting developments in the area of targeted interventions, both in diagnostic and therapeutic areas. The past two decades have also whitnessed substantial advances in biomedical technology, advances that have contributed substantially to accelerating the pace of discovery.

This is the fourth volume of the series Progress in Anti-Cancer Therapy. This volume mainly covers: five types of cancer (breast, prostate, bladder, lymphoma and ovarian), the role of HIV and HTLV in cancer, and some developmental pharmacology and behavioral issues. It particularly focuses on one of the most common cancers: prostate cancer. Other covered points are: review of all trials reported in order to update our practices in bladder cancer; description of new drugs which should be integrated in the treatment of metastatic breast cancer, a summary of conceptual advances on our therapeutic approach to none-metastatic breast cancer; excellent review of the current knowledge and perspectives on the treatment of ovarian cancer; description of the state of the art regarding the use of sentinel node biopsy in melanoma patients and on the same hand an exhaustive overview on the emerging new drugs for the treatment of human lymphomas.

This book includes some selected presentations given at the 3rd International Congress on Neo-Adjuvant Chemotherapy which was held in Paris from February 6th to February 9th, 1991. It was attended by over 2000 physicians from around the world and by 700 nurses. Its organisation was saddened by the untimely death of Professor Claude Jacquillat on October 12th, 1990. It was further complicated in January and February 1991 by the gulf events which led some guests to cancel their participation. However with the outstanding help of the two presidents cho­ sen by Claude Jacquillat before his death, Pierre Banzet from Paris and James F. Holland from New York, the organizers could set up an exciting meeting confirming the impact of neo-adjuvant chemotherapy on relatively new indi­ cations such as non-small lung cancers, bladder cancer, esophagal cancer, cer­ vix cancer, etc ... It is noteworthy that a contradictory debate on primary chemotherapy in non-small lung cancer turned into a consensus conference. In breast cancer, the downstaging induced by primary chemotherapy is ack­ nowledged by all and the conviction that Jacquillat defended so heartily that breast preservation should be proposed to all patients with breast cancer what­ ever their tumour size is shared now by more and more people. A special emphasis was given to new drugs, new combination, new access (locoregional therapy) and new developments such as that of growth factors and of interleukin 2.